{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017412","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.040850+00:00","generated_at":"2026-06-09T00:34:33.511324+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mustang Bio's MB-106 CAR-T interim data selected for ASH; complete responses in FL","bullets":["Interim Phase 1/2 data for MB-106 (CD20-targeted CAR-T) accepted as poster at ASH Dec 9-12, 2023.","At dose level 1 (3.3x10^6 cells/kg): two FL patients achieved complete response, WM patient VGPR, HCL-v stable disease with transfusion independence.","Safety: 3 patients Grade 1 CRS, no ICANS or dose-limiting toxicities; outpatient infusion allowed.","Patients heavily pre-treated (median 5.5 prior lines); WM patient had nine prior treatments including auto-SCT.","Pivotal Phase 2 WM trial expected to start mid-2024 with top-line data possible by mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017412","json":"https://secwatch.observer/filing/0001558370-23-017412.json","markdown":"https://secwatch.observer/filing/0001558370-23-017412.md","text":"https://secwatch.observer/filing/0001558370-23-017412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/0001558370-23-017412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/tmb-20231102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:34:33.511324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}